

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	INTEGRAL DIAGNOSTICS LIMITED
ABN	55 130 832 816

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ian Kadish
Date of last notice	5 March 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	28 August 2025
No. of securities held prior to change	<u>Ordinary Shares</u> 610,476 fully paid ordinary shares <u>Performance Rights (Rights) relating to LTI Plan</u> 157,371 Rights approved by Shareholders 5 Nov 2021 241,591 Rights approved by Shareholders 4 Nov 2022 248,970 Rights approved by Shareholders 29 Nov 2023 <u>327,566</u> Rights approved by shareholders 1 Nov 2024 975,498 Rights <u>Performance Rights FY24 STIs relating to STI Plan</u> 29,072 STI Rights approved by shareholders 29 Nov 2023
Class	Performance Rights (Rights) relating to LTI Plan
Number acquired	Nil

Appendix 3Y
Change of Director's Interest Notice

Number disposed	398,962
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p><u>Ordinary Shares</u> 610,476 fully paid ordinary shares</p> <p><u>Performance Rights (Rights) relating to LTI Plan</u> 248,970 Rights approved by Shareholders 29 Nov 2023 327,566 Rights approved by shareholders 1 Nov 2024 576,536 Rights</p> <p><u>Performance Rights FY24 STIs relating to STI Plan</u> 29,072 STI Rights approved by shareholders 29 Nov 2023</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of rights issued to CEO pursuant to Company's FY22 and FY23 LTI Plans

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.